Tocilizumab (RoActemra) for Adults with Systemic Sclerosis – Second Line

featured image
Indications: Systemic sclerosis
Therapeutic Areas: Dermatology , Respiratory System
Year: 2017

There is currently no cure for systemic sclerosis and treatment options focus on the management of symptoms. Tocilizumab is intended for the treatment of systemic sclerosis in adults. It is currently in development and early research indicates that it is able to target the key mechanisms thought to be responsible for the disease. If licensed, it could provide a new treatment option for adults with systemic sclerosis.